Rheumatische Erkrankungen bei Diabetes mellitus

ZUSAMMENFASSUNG

Erkrankungen des Bewegungsapparats gehören zu den häufigsten Vorstellungsgründen in einer Hausarztpraxis. Wichtig ist in dem Zusammenhang ein frühzeitiges Erkennen und präventives Vorgehen zum Erhalt der Lebensqualität und Vermeidung von Morbidität. Ein Diabetes mellitus stellt für einige Erkrankungen einen wichtigen prädiktiven sowie verlaufsbestimmenden Faktor dar. Dieser Artikel zielt darauf ab, Ihnen das Wissen über die Erkrankungen und ihre Entstehung, praktische diagnostische Möglichkeiten sowie Therapieoptionen zu vermitteln und soll damit eine individuelle Behandlungsstrategie ermöglichen.

Publication History

Article published online:
25 June 2021

• Literatur

• 1 Arkkila PE, Kantola IM, Viikari JS. Limited joint mobility in non-insulin-dependent diabetic (NIDDM) patients: correlation to control of diabetes, atherosclerotic vascular disease, and other diabetic complications. J Diabetes Complications. 1997; 11: 208-217 DOI: 10.1016/s1056-8727(96)00038-4.
• 2 Smith LL, Burnet SP, McNeil JD. Musculoskeletal manifestations of diabetes mellitus. Br J Sports Med 2003; 37: 30-35 DOI: 10.1136/bjsm.37.1.30.
• 3 Sauseng S, Kästenbauer T, Irsigler K. Limited joint mobility in selected hand and foot joints in patients with type 1 diabetes mellitus: a methodology comparison. Diabetes Nutr Metab 2002; 15: 1-6
• 4 Sözen T, Başaran NÇ, Tınazlı M, Özışık L. Musculoskeletal problems in diabetes mellitus. Eur J Rheumatol. 2018; 5: 258-265 DOI: 10.5152/eurjrheum.2018.18044.
• 5 Grazina R, Teixeira S, Ramos R. et al Dupuytren’s disease: where do we stand?. EFORT Open Rev 2019; 4: 63-69 DOI: 10.1302/2058-5241.4.180021.
• 6 Becker K, Siegert S, Toliat MR. et al German Dupuytren Study Group. Meta-Analysis of genome-wide association studies and network analysis-based integration with gene expression cata identify new suggestive loci and unravel a Wnt-centric network associated with Dupuytren’s disease. PLoS One 2016; 11: e0158101 DOI: 10.1371/journal.pone.0158101.
• 7 Balaguer T, David S, Ihrai T. et al Histological staging and Dupuytren’s disease recurrence or extension after surgical treatment: a retrospective study of 124 patients. J Hand Surg Eur Vol 2009; 34: 493-496 DOI: 10.1177/1753193409103729.
• 8 Ball C, Izadi D, Verjee LS. et al Systematic review of non-surgical treatments for early dupuytren’s disease. BMC Musculoskelet Disord 2016; 17: 345 DOI: 10.1186/s12891-016-1200-y.
• 9 Hurst LC, Badalamente MA, Hentz VR. et al Injectable collagenase clostridium histolyticum for Dupuytren’s contracture. N Engl J Med 2009; 361: 968-979 DOI: 10.1056/NEJMoa0810866.
• 10 Räisänen MP, Karjalainen T, Göransson H. et al Dupuytren Treatment Effectiveness Trial (DETECT): a protocol for prospective, randomised, controlled, outcome assessor-blinded, three- armed parallel 1:1:1, multicentre trial comparing the effectiveness and cost of collagenase clostridium histolyticum, percutaneous needle fasciotomy and limited fasciectomy as short-term and long-term treatment strategies in Dupuytren’s contracture. BMJ Open 2018; 8: e019054 DOI: 10.1136/bmjopen-2017-019054.
• 11 Zah V, Pelivanovic J, Tatovic S, Vukicevic D. et al Healthcare costs and resource use of patients with Dupuytren Ccontracture treated with collagenase clostridium histolyticum or fasciectomy: a propensity matching analysis. Clinicoecon Outcomes Res 2020; 12: 635-643 DOI: 10.2147/CEOR.S269957.
• 12 Van Rijssen AL, ter Linden H, Werker PM. Five-year results of a randomized clinical trial on treatment in Dupuytren’s disease: percutaneous needle fasciotomy versus limited fasciectomy. Plast Reconstr Surg 2012; 129: 469-477 DOI: 10.1097/PRS.0b013e31823aea95.
• 13 Mun SW, Baek CH. Clinical efficacy of hydrodistention with joint manipulation under interscalene block compared with intra-articular corticosteroid injection for frozen shoulder: a prospective randomized controlled study. J Shoulder Elbow Surg 2016; 25: 1937-1943 DOI: 10.1016/j.jse.2016.09.021.
• 14 Dias R, Cutts S, Massoud S. Frozen shoulder. BMJ 2005; 331: 1453-1456 DOI: 10.1136/bmj.331.7530.1453.
• 15 Jeanmonod R, Harberger S, Waseem M.. Trigger Finger. 2020. In: StatPearls [Internet] Treasure Island (FL). StatPearls Publishing. Im Internet. https://www.ncbi.nlm.nih.gov/books/NBK459310/ Stand:20.12.2020
• 16 Merry SP, O’Grady JS, Boswell CL. Trigger finger? Just shoot! J Prim Care Community Health. 2020; 11: 2150132720943345. doi:10.1177/2150132720943345.
• 17 McKee D, Lalonde J, Lalonde D. How Many Trigger Fingers Resolve Spontaneously Without Any Treatment?. Plast Surg (Oakv) 2018; 26: 52-54 DOI: 10.1177/2292550317740691.
• 18 Fiorini HJ, Tamaoki MJ, Lenza M. et al Surgery for trigger finger. Cochrane Database Syst Rev. 2018; 2: CD009860 DOI: 10.1002/14651858.CD009860.pub2.
• 19 Bland JD. Carpal tunnel syndrome. BMJ 2007; 335: 343-346 DOI: 10.1136/bmj.39282.623553.AD.
• 20 De Rijk MC, Vermeij FH, Suntjens M. et al Does a carpal tunnel syndrome predict an underlying disease?. J Neurol Neurosurg Psychiatry 2007; 78: 635-637 DOI: 10.1136/jnnp.2006.102145.
• 21 Ostergaard PJ, Meyer MA, Earp BE. Non-operative treatment of carpal tunnel syndrome. Curr Rev Musculoskelet Med 2020; 13: 141-147 DOI: 10.1007/s12178-020-09616-0.
• 22 Piazzini DB, Aprile I, Ferrara PE. et al A systematic review of conservative treatment of carpal tunnel syndrome. Clin Rehabil 2007; 21: 299-314 DOI: 10.1177/0269215507077294.
• 23 Abate M, Schiavone C, Salini V. et al Occurrence of tendon pathologies in metabolic disorders. Rheumatology (Oxford) 2013; 52: 599-608 DOI: 10.1093/rheumatology/kes395.
• 24 Yang L, Zhang J, Ruan D. et al Clinical and structural outcomes after rotator cuff repair in patients with diabetes: a meta-analysis. Orthop J Sports Med 2020; 8: 2325967120948499 DOI: 10.1177/2325967120948499.
• 25 Trujillo-Santos AJ. Diabetic muscle infarction: an underdiagnosed complication of long- standing diabetes. Diabetes Care 2003; 26: 211-215 DOI: 10.2337/diacare.26.1.211.
• 26 Yong TY, Khow KSF. Diabetic muscle infarction in end-stage renal disease: a scoping review on epidemiology, diagnosis and treatment. World J Nephrol 2018; 7: 58-64 DOI: 10.5527/wjn.v7.i2.58.
• 27 Morcuende JA, Dobbs MB, Crawford H. et al Diabetic muscle infarction. Iowa Orthop J 2000; 20: 65-74
• 28 Pappone N, Ambrosino P, Di Minno MND. et al Is diffuse idiopathic skeletal hyperostosis a disease or a syndrome?. Rheumatology (Oxford) 2017; 56: 1635-1636 DOI: 10.1093/rheumatology/kew451.
• 29 Yunoki M, Suzuki K, Uneda A. The importance of recognizing diffuse idiopathic skeletal hyperostosis for neurosurgeons: a review. Neurol Med Chir (Tokyo) 2016; 56: 510-515 DOI: 10.2176/nmc.ra.2016-0013.
• 30 Mader R. Diffuse idiopathic skeletal hyperostosis: time for a change. J Rheumatol 2008; 35: 377-379
• 31 Mader R, Baraliakos X, Eshed I. et al Imaging of diffuse idiopathic skeletal hyperostosis (DISH). RMD Open 2020; 6: e001151 DOI: 10.1136/rmdopen-2019-001151.